NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
CStone Pharmaceuticals
Nanjing Leads Biolabs Co.,Ltd
Merck Sharp & Dohme LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Providence Health & Services
Shanghai Junshi Bioscience Co., Ltd.